A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

87

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Breast Cancer
Colorectal Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Acral Lentiginous Melanoma
Head and Neck Squamous Cell Carcinoma
Hepatocellular Carcinoma
Esophageal Squamous Cell Carcinoma
Urothelial Carcinoma
DMMR Colorectal Cancer
MSI-H Colorectal Cancer
Melanoma
Platinum-Resistant Primary Peritoneal Carcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Epithelial Ovarian Cancer
Triple Negative Breast Cancer

Interventions

BIOLOGICAL: ATRC-101
BIOLOGICAL: Pembrolizumab
DRUG: Pegylated liposomal doxorubicin (PLD)

Sponsor

Atreca, Inc.